Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Halpern

Showing results (211-220 of 250) with videos related to

Pageof 25
Sort By:
Transplantation and Cellular Therapy|November 5, 2025
National Landscape of Logistical and Nonmedical Requirements for Transplantation and Cellular TherapyHannah R Abrams, Helene Starks, Lindsey Bandini, et al.
Environmental Management|November 17, 2016
Visions of Restoration in Fire-Adapted Forest Landscapes: Lessons from the Collaborative Forest Landscape Restoration ProgramLauren S Urgenson, Clare M Ryan, Charles B Halpern, et al.
Leukemia & Lymphoma|March 23, 2021
Effect of post-treatment MRD status on subsequent outcomes according to chemotherapy intensity in acute myeloid leukemia (AML)Michael J Hochman, Megan Othus, Roland B Walter, et al.
Leukemia & Lymphoma|March 9, 2023
Poor post-induction outcomes in patients with acute myeloid leukemia previously treated with hypomethylating agentsMichelle Y Zhang, Megan Othus, Carole Shaw, et al.
Haematologica|July 11, 2019
Impact of clinical, cytogenetic, and molecular profiles on long-term survival after transplantation in patients with chronic myelomonocytic leukemiaJanghee Woo, Dae Ro Choi, Barry E Storer, et al.
Haematologica|July 11, 2020
Survival of patients with newly diagnosed high-grade myeloid neoplasms who do not meet standard trial eligibilityMary-Elizabeth M Percival, Megan Othus, Sarah Mirahsani, et al.
Leukemia|January 21, 2022
Outcomes based on treatment setting in refractory acute myeloid leukemia and other high-grade myeloid malignanciesNoam E Kopmar, Megan Othus, Kelda M Gardner, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|March 5, 1981
New metabolites in isovaleric acidemiaR J Truscott, D Malegan, E McCairns, et al.
Leukemia|November 14, 2019
Need for routine examination of left ventricular ejection fraction in patients with AMLHiba M Khan, Kelda M Gardner, Carole Shaw, et al.
Leukemia & Lymphoma|February 21, 2020
Randomized phase 1 study of sequential ("primed") vs. concurrent decitabine in combination with cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M) in adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-grade myeloid neoplasmRaffaele Palmieri, Sarah A Buckley, Megan Othus, et al.
Pageof 25

Showing results (211-220 of 250) with videos related to

Sort By:
Pageof 25
Transplantation and Cellular Therapy|November 5, 2025
National Landscape of Logistical and Nonmedical Requirements for Transplantation and Cellular TherapyHannah R Abrams, Helene Starks, Lindsey Bandini, et al.
Environmental Management|November 17, 2016
Visions of Restoration in Fire-Adapted Forest Landscapes: Lessons from the Collaborative Forest Landscape Restoration ProgramLauren S Urgenson, Clare M Ryan, Charles B Halpern, et al.
Leukemia & Lymphoma|March 23, 2021
Effect of post-treatment MRD status on subsequent outcomes according to chemotherapy intensity in acute myeloid leukemia (AML)Michael J Hochman, Megan Othus, Roland B Walter, et al.
Leukemia & Lymphoma|March 9, 2023
Poor post-induction outcomes in patients with acute myeloid leukemia previously treated with hypomethylating agentsMichelle Y Zhang, Megan Othus, Carole Shaw, et al.
Haematologica|July 11, 2019
Impact of clinical, cytogenetic, and molecular profiles on long-term survival after transplantation in patients with chronic myelomonocytic leukemiaJanghee Woo, Dae Ro Choi, Barry E Storer, et al.
Haematologica|July 11, 2020
Survival of patients with newly diagnosed high-grade myeloid neoplasms who do not meet standard trial eligibilityMary-Elizabeth M Percival, Megan Othus, Sarah Mirahsani, et al.
Leukemia|January 21, 2022
Outcomes based on treatment setting in refractory acute myeloid leukemia and other high-grade myeloid malignanciesNoam E Kopmar, Megan Othus, Kelda M Gardner, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|March 5, 1981
New metabolites in isovaleric acidemiaR J Truscott, D Malegan, E McCairns, et al.
Leukemia|November 14, 2019
Need for routine examination of left ventricular ejection fraction in patients with AMLHiba M Khan, Kelda M Gardner, Carole Shaw, et al.
Leukemia & Lymphoma|February 21, 2020
Randomized phase 1 study of sequential ("primed") vs. concurrent decitabine in combination with cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M) in adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-grade myeloid neoplasmRaffaele Palmieri, Sarah A Buckley, Megan Othus, et al.
Pageof 25